

Commercial Development of Trimetasphere Metallofullerene MRI Contrast Agents

To cite this article: Stephen R. Wilson et al 2007 Meet. Abstr. MA2007-01 1127

View the <u>article online</u> for updates and enhancements.

You may also like

- <u>Novel Magnetic Resonance Imaging</u> <u>Contrast Agents Based on Trimetallic</u> <u>Nitride Endohedral Metallofullerenes</u> Chunying Shu, Jianfei Zhang, Jonathan Reid et al.
- <u>Trimetasphere Metallofullerene MRI</u> <u>Contrast Agents with High Molecular</u> <u>Relaxivity</u> Darren R. MacFarland
- <u>Hydrogenation of Trimetallic Nitride</u> <u>Endohedral Metallofullerenes</u> Wujun Fu, Harry Gibson and Harry Dorn




This content was downloaded from IP address 3.14.130.24 on 01/05/2024 at 02:44

Commercial Development of TrimetasphereTM Metallofullerene MRI Contrast Agents

Stephen R. Wilson, Darren MacFarland, Zhiguo Zhou, Jason Zhang, and Rajesh Shukla Luna nanoWorks, a Division of Luna Innovations Inc. 521 Bridge Street Danville, VA 24541 www.lunananoworks.com

Luna nanoWorks is a new division of Luna Innovations Inc. (Nasdaq: LUNA) created to commercialize medical products based on nanomaterials technology.



Hydration shell around Gd₃N@C₈₀

One of Luna nanoWorks' technologies is a unique fullerene species we call a TrimetasphereTM -- an 80 carbon fullerene sphere in which a trimetallic nitride complex is embedded. The goal of our MRI program is to provide safer, more effective contrast agents to enable earlier detection of disease and superior patient profiling. I will discuss the large scale TrimetasphereTM manufacturing process, and the chemical synthesis, biology, and MRI imaging properties of some of Luna's unique TrimetasphereTM contrast agents.